Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa

被引:42
作者
Kaye, KS
Kanafani, ZA
Dodds, AE
Engemann, JJ
Weber, SG
Carmeli, Y
机构
[1] Duke Univ, Med Ctr, Div Infect Dis, Durham, NC 27710 USA
[2] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
关键词
D O I
10.1128/AAC.00060-06
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Due to the greater in vitro activity of ciprofloxacin than that of levofloxacin against Pseudomonas aeruginosa, the likelihood of isolating a clinical strain of quinolone-resistant (QR) P. aeruginosa might be greater after exposure to levofloxacin than ciprofloxacin. We examined the risk of isolating QR P. aeruginosa in association with prior levofloxacin or ciprofloxacin exposure. A case-case-control study was conducted. Two groups of cases, one with nosocomial QR P. aeruginosa infections and one with nosocomial quinolone-susceptible (QS) P. aeruginosa infections, were compared to a control group of hospitalized patients without P. aeruginosa infections. Bivariable and multivariable analyses were used to determine risk factors for isolation of QR P. aeruginosa and QS P. aeruginosa. One hundred seventeen QR P. aeruginosa and 255 QS P. aeruginosa cases were identified, and 739 controls were selected. Exposures to ciprofloxacin were similar among all three groups (8% for controls, 9.4% for QR P. aeruginosa cases, and 7.5% for QS P. aeruginosa cases; P >= 0.6). Levofloxacin use was more frequent in the QR P. aeruginosa cases than in the controls (35.9% and 22.1%, respectively; odds ratio [OR] = 2.0; 95% confidence interval [CI] = 1.3 to 3.0) and less frequent in QS P. aeruginosa cases (14.1% of QS P. aeruginosa cases; OR = 0.6; 95% CI = 0.4 to 0.9). In multivariable analysis, levofloxacin, but not ciprofloxacin, was a significant risk factor for isolation of QR P. aeruginosa (OR for levofloxacin = 1.7 [95% CI = 1.0 to 2.91; OR for ciprofloxacin = 1.2 [95% CI = 0.6 to 2.51). Levofloxacin was associated with a reduced risk of isolation of QS P. aeruginosa (OR = 0.6; 95% CI = 0.4 to 0.9), whereas ciprofloxacin had no significant effect (OR = 1.0; 95% CI = 0.6 to 1.8). In conclusion, the use of levofloxacin, but not ciprofloxacin, was associated with isolation of QR P. aeruginosa.
引用
收藏
页码:2192 / 2196
页数:5
相关论文
共 30 条
[1]   Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in US hospitals [J].
Bhavnani, SM ;
Callen, WA ;
Forrest, A ;
Gilliland, KK ;
Collins, DA ;
Paladino, JA ;
Schentag, JJ .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2003, 60 (19) :1962-1970
[2]   Clinical isolation and resistance patterns of and superinfection with 10 nosocomial pathogens after treatment with ceftriaxone versus ampicillin-sulbactam [J].
Carmeli, Y ;
Castro, J ;
Eliopoulos, GM ;
Samore, MH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :275-279
[3]  
Favero MS, 1996, AM J INFECT CONTROL, V24, P380
[4]   Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals [J].
Fridkin, SK ;
Hill, HA ;
Volkova, NV ;
Edwards, JR ;
Lawton, RM ;
Gaynes, RP ;
McGowan, JE .
EMERGING INFECTIOUS DISEASES, 2002, 8 (07) :697-701
[5]   Antimicrobial susceptibility patterns in Pseudomonas aeruginosa:: Data from a multicenter intensive care unit Surveillance Study (ISS) in the United States [J].
Friedland, I ;
Gallagher, G ;
King, T ;
Woods, GL .
JOURNAL OF CHEMOTHERAPY, 2004, 16 (05) :437-441
[6]   Levofloxacin and ciprofloxacin in vitro activities against 4,003 clinical bacterial isolates collected in 24 Italian laboratories [J].
Gesu, GP ;
Marchetti, F ;
Piccoli, L ;
Cavallero, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (02) :816-819
[7]   Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients [J].
Harris, AD ;
Perencevich, E ;
Roghmann, MC ;
Morris, G ;
Kaye, KS ;
Johnson, JA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :854-858
[8]   Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients [J].
Harris, AD ;
Smith, D ;
Johnson, JA ;
Bradham, DD ;
Roghmann, MC .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (03) :340-345
[9]   Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa [J].
Higgins, PG ;
Fluit, AC ;
Milatovic, D ;
Verhoef, J ;
Schmitz, FJ .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2003, 21 (05) :409-413
[10]   Emerging mechanisms of fluoroquinolone resistance [J].
Hooper, DC .
EMERGING INFECTIOUS DISEASES, 2001, 7 (02) :337-341